DENVER – Lung cancer survivor Kathy Weber is using the strength she demonstrated during her recovery to accept a new challenge: Helping others. In order to help more attention and assistance to the International Association for the Study of Lung Cancer (IASLC) in its goal to conquer thoracic malignancies around the world, Kathy is taking part in Team Draft’s 2016 Lung Cancer Survivors Super Bowl Challenge, raising money to help further cancer research and create new ways to treat the disease.
DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased to hear of another approval by the U.S. Food and Drug Administration (FDA) that helps in the fight against lung cancer – the fourth in two months. The FDA approved necitumumab (PortrazzaTM) in combination with standard chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for their advanced disease.
November is known in the U.S. for the holiday of “Thanksgiving,” celebrating the good fortunes of the previous year. The past year has seen continuing significant advances in the management of lung cancer, with more to come.
The International Association for the Study of Lung Cancer (IASLC) is hosting a Lung Cancer Awareness Forum for health professionals, patients and advocates at the IASLC headquarters in Aurora, Colo. on Nov. 23, 2015 from 5 p.m. to 7 p.m. MST.
DENVER – As part of Lung Cancer Awareness Month in November, the International Association for the Study of Lung Cancer (IASLC) today announced a new global initiative to create a set of Patient/Provider Lung Cancer Information Cards to create better communication and understanding between physicians, patients and their families with the goal of improving collaboration and better treatment outcomes around the world.
DENVER – The International Association for the Study of Lung Cancer (IASLC) commends the U.S. Food and Drug Administration’s (FDA) decision to grant accelerated approval for osimertinib (TagrissoTM), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.